characterized by relapses during which new symptoms may occur and old ones worsen, and remissions during which the patient fully or partially recovers from the deficits acquired during the relapse. 13 
Efficacy of Current First-line Disease-modifying Treatments
The formation of the inflammatory lesions that characterize MS is significantly reduced disability progression as determined by change in EDSS score compared with placebo 17-21 (see Table 1 ). However, these treatments show only moderate efficacy and most MS patients still show disease progression. The majority (62-75%) of patients relapse within two years, and 20-27% of patients worsen by ≥1 point on the EDSS within two years. Moreover, adherence to DMT treatment regimens is problematic, largely due to side effects such as injection-site reactions and influenza-like symptoms. A chart-based study in Ireland on 394 MS patients determined an overall IFNβ stopping rate of 28% over five years. 22 The study also showed a significant difference between the IFNβ stopping rates for RRMS (14%) and SPMS (23%) after three years (p=0.0003). Patients were shown to stop IFNβ due to side effects after a median of 13 months, and due to treatment failure after a median of 35 months (p=0.0004). Furthermore, many patients with MS have breakthrough disease activity despite therapy with these agents, or are unresponsive to treatment. 23 Therefore, there is a continuing and substantially unmet need for more effective treatments that limit relapses and disease progression within MS.
Natalizumab (Tysabri ® ) is a recently introduced recombinant humanized anti-α 4 -integrin antibody that is generally reserved for second-line use in MS, although it can be used as a first-line agent in cases of rapidly evolving severe RRMS. 24 The aim of this article is to review the broad spectrum of efficacy of natalizumab across traditional and non-traditional outcomes from clinical trials and postmarketing studies.
Mode of Action of Natalizumab
Natalizumab is the first α 4 -integrin antagonist in the class of selective adhesion molecule (SAM) inhibitors. It is a humanized monoclonal antibody that binds to α 4 -integrin on the surface of activated T cells, which prevents adhesion between the T cell and the endothelial cell and disrupts the resulting inflammatory cascade. Natalizumab has three putative modes of action (see Figure 1) . It decreases leukocyte treatment alone for 120 weeks in 1,171 patients with RRMS. 23 The sample cohorts in both trials were large compared with previous trials of DMTs (see Table 1 ). Since natalizumab is currently only recommended as a monotherapy, this article will focus on the AFFIRM study.
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The AFFIRM Study
The AFFIRM study was a large phase III clinical trial. Eligibility requirements were age 18-50 years, a diagnosis of RRMS, one or more documented clinical relapses within the prior 12 months, EDSS between 0 and 5.0, and having magnetic resonance imaging (MRI) lesions consistent with MS. 25 The primary end-points of the study were the rate of clinical relapse at one year and the rate of sustained disability progression at two years, which was defined as an increase of 1.0 or more on the EDSS from a baseline score of 1.0 or more or an increase of 1.5 or more from a baseline score of 0 that was sustained for 12 weeks (progression could not be confirmed during a relapse). Patients were randomized to natalizumab 300mg (n=627) or placebo (n=315) by intravenous infusions every four weeks for up to 30 infusions. Neurological evaluations were carried out every 12 weeks, and proton-density-weighted or T 2 -weighted and gadolinium-enhanced T 1 -weighted MRI scans of the brain were performed at baseline and weeks 52 and 104. Patients had a mean age of 36.7 and 35.6 years and 67 and 72% were female in the placebo and natalizumab groups, respectively. Demographics and MS disease histories were similar between the two groups.
Natalizumab demonstrated substantial benefit over two years compared with placebo not only in the overall population but also in the subgroup of highly active patients, who were defined as having at least two relapses in the previous year and at least one gadolinium-enhancing lesion at baseline. The rate of clinical relapse was reduced by 68%
(p<0.001) in one year in the overall population, which was sustained at two years (see Figure 2) , and by 81% (p<0.001) in the highly active population. 26 The risk of a sustained progression of disability (defined as EDSS progression sustained at 12 and 24 weeks) was reduced by 42-54% (p<0.001), and by 53-64% (p=0.029 and p=0.008) versus placebo in the highly active population. During an open-label extension study of the AFFIRM trial, the low ARR was maintained and there was minimal progression in EDSS during the third year of natalizumab therapy. 27 Efficacy of natalizumab on MRI measures of disease activity was also demonstrated. Over two years, the mean number of new or enlarging T 2 -hyperintense MRI lesions was reduced by 83% (p<0.001), and new lesions detected by gadolinium-enhanced MRI were reduced by 92% (p<0.001).
Within this trial, natalizumab had an acceptable safety and tolerability profile, and the only adverse events occurring significantly more frequently in the natalizumab group than in the placebo group were fatigue and allergic reactions. Hypersensitivity reactions were seen in 4% of patients receiving natalizumab, and serious hypersensitivity reactions were seen in 1%. 25 A retrospective analysis of the AFFIRM data showed that in patients with a baseline EDSS ≥2, treatment with natalizumab significantly increased the probability of sustained improvement in disability (defined as a onepoint decrease in EDDS score sustained for 12 weeks) by 69% relative to placebo (p=0.006). Furthermore, patients with highly active disease showed a 143% improvement over placebo (p=0.045). 32 The mechanisms underlying these improvements are not yet understood. However, preliminary data from post-marketing studies indicate that natalizumab promotes neuronal remyelination, particularly in RRMS, but further investigations are required to validate this finding. 33 Other recent analyses showed a 164% increase relative to placebo in freedom from clinical disease activity (p<0.0001, defined as absence of relapses and sustained clinical progression as measured by EDSS) and a four-fold increase over placebo in freedom from radiological disease activity (p<0.0001, defined as absence of gadolinium-enhancing lesions and absence of new or enlarging T 2 -hyperintensive lesions) over two years. When the results were expressed as a composite of clinical and radiological measures, the improvement in the treatment group was fivefold higher than that in the placebo group, suggesting that disease remission may become a realistic treatment goal in the future. In the highly active disease subgroup, the proportion of natalizumab-treated patients who were disease-free at two years represented a 16-fold improvement relative to placebo (see Figure 3) . The effect of natalizumab treatment was greatest in the second year, indicating that efficacy may increase over time.
Non-traditional Outcomes
U S N E U R O L O G Y
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A long-term study followed up a subgroup of 23 MS patients who had previously been enrolled in two phase III trials evaluating natalizumab. 35 At 14 months after natalizumab treatment cessation, no clinical, radiographic, or immunological rebound phenomena were observed. In addition, decreased lymphocyte numbers and altered cell ratios returned to normal during this period, and no infectious complications were observed. These findings from a limited patient population suggest that recurrence of disease and other complications may not be problematic, at least during the period of observation, after cessation of natalizumab.
The effects of natalizumab treatment cessation were investigated by analysing data from a large-scale safety extension 36 that included patients who had participated in the AFFIRM study, 25 the SENTINEL study, 23 and the GLatiramer Acetate and Natalizumab Combination Evaluation (GLANCE) safety study (a phase II study of natalizumab with glatiramer acetate versus placebo with glatiramer acetate in 110 patients with RRMS over 24 weeks). 37 The safety extension study was of natalizumab was similar to that seen in the AFFIRM study. 25 A health economic study on natalizumab in the UK concluded that natalizumab therapy is cost-effective in all patients with highly active RRMS compared with current DMTs.
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Long-term Safety
Natalizumab was voluntarily withdrawn from the market one year after its FDA approval in 2004 following three confirmed cases of PML in two patients from the SENTINEL study and in one patient with Crohn's disease. 39, 40 The FDA and European Medicines Agency (EMEA)
re-approved natalizumab with revised labeling in 2006, and it is now recommended only as monotherapy. 41 In the US, natalizumab is available to prescribers only through a registry called Tysabri Outreach:
Unified Commitment to Health (TOUCH). In TOUCH, patients are screened for PML symptoms before each natalizumab infusion. 42 Since the re-launch of natalizumab in 2006, rare cases of PML have been confirmed in patients exposed to monotherapy. 43 As of November 30, 2009, 28 cases of PML have been confirmed in more than 60,000 natalizumab-treated patients in the post-marketing setting. 43 It should be noted that the absolute number of PML cases must be evaluated in the larger context of the number of patients actually exposed to natalizumab. Therefore, the actual number of PML cases is a less informative measure than the incidence rate. The duration of natalizumab dosing prior to PML diagnosis ranged from approximately one year to more than 3.5 years (12-44 infusions), while the incidence of PML generally increases with duration of exposure, as shown in Figure 4 . The rate of PML is consistent with that seen in pre-approval clinical trials. There is, however, limited experience in patients who received more than three years of natalizumab treatment.
To date, clinical signs and symptoms that prompted evaluation for PML in natalizumab-treated patients have been new or worsening neurological symptoms evolving over several weeks, focal neurological signs and other symptoms, such as hemiparesis, focal myoclonia, aphasia, retrochiasmal visual deficits, and changes in cognition, behavior, and personality.
MRI assessments of PML cases typically revealed non-enhancing T 2 -hyperintense lesions in frontal, temporal, parietal, or occipital regions. Many of these lesions were unifocal, and gadoliniumenhancing lesions were identified. JC virus DNA has been observed in the cerebrospinal fluid of patients with PML when analysed using the polymerase chain reaction. In most patients, however, titers were low (<500 copies/ml). In PML not associated with natalizumab, new or worsening neurological signs or symptoms, changes in mental status, seizure, or fever were usually not associated with gadoliniumenhancing lesions. 44 At present, there are multiple long-term evaluation programs in progress that are designed to further characterize the longterm safety and efficacy of natalizumab (see Table 3 ). There are currently insufficient data on the efficacy and safety of natalizumab in patients with progressive forms of MS to recommend its use in primary or secondary progressive MS. 
